Who is sponsoring NCT07316660?

NCT07316660 is sponsored by Benha University.

What drugs are being tested in NCT07316660?

Interventions in NCT07316660: Palmitoylethanolamide (PEA), Ibuprofen (Brufen®).

Is NCT07316660 still recruiting?

NCT07316660 is currently not yet recruiting. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT07316660

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Palmitoylethanolamide vs Ibuprofen for Pain After ESWL

Not yet recruiting NA Last updated 5 January 2026

What this trial tests

NA trial testing Palmitoylethanolamide (PEA) in Pain After Extracorporeal Shock Wave Lithotripsy in 120 participants. Not yet recruiting.

Timeline

1 January 2026

Primary endpoint
1 June 2026

1 July 2026

Quick facts

Lead sponsor	Benha University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	1 January 2026
Primary completion	1 June 2026
Estimated completion	1 July 2026
Sites	1 location across Egypt

Drugs / interventions tested

Palmitoylethanolamide (PEA) — full drug profile →
Ibuprofen (Brufen®) — full drug profile →

Conditions studied

Pain After Extracorporeal Shock Wave Lithotripsy — all drugs for Pain After Extracorporeal Shock Wave Lithotripsy →
Palmitoylethanolamide — all drugs for Palmitoylethanolamide →

Sponsor

Benha University

Who can join

Adults 18 to 65, any sex, with Pain After Extracorporeal Shock Wave Lithotripsy or Palmitoylethanolamide. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pain after extracorporeal shock wave lithotripsy (ESWL), a non-surgical procedure used to treat kidney stones, is common and is usually treated with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. However, NSAIDs may cause side effects in some patients, including stomach irritation and kidney problems. Palmitoylethanolamide (PEA) is a naturally occurring substance in the body with anti-inflammatory and pain-relieving properties and has been shown to be safe in previous studies. This study aims to compare the effectiveness of PEA with ibuprofen for controlling acute postoperative pain after ESWL. Participants undergoing ESWL will be randomly assigned to receive either oral PEA or oral ibuprofen. Pain intensity will be measured using a visual analogue scale during the first 24 hours after the procedure. The use of rescue pain medication and any side effects will also be recorded. The results of this study may help determine whether PEA can be an effective alternative to ibuprofen for the management of acute pain after ESWL.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Palmitoylethanolamide (PEA)

Trials testing the same drug.

NCT06229977 — A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression · Phase 2 · completed

Other Benha University trials

Trials by the same sponsor.

NCT07526675 — Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer · NA · not yet recruiting
NCT07480031 — Determination of the Optimal Inspiratory Pressure to Decrease Incidence of Gastric Insufflation With Adequate Ventilatio · NA · not yet recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07467356 — Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip · Phase 3 · recruiting
NCT07300787 — miRNA in Pediatric Gastritis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07316660 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Benha University
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07316660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing